Summary:
- This article discusses Aptar's nasal vaccine delivery solutions being featured in the CastleVax Phase II clinical trial of an intranasal COVID-19 vaccine candidate.
- Aptar's nasal delivery technology is being used to administer the COVID-19 vaccine through the nose, which could provide an alternative to traditional injectable vaccines.
- The intranasal vaccine delivery method may offer advantages such as ease of administration and the potential to stimulate immune responses in the respiratory system, which is the primary entry point for the COVID-19 virus.